Fenoldopam mesylate | CAS#67227-57-0

Fenoldopam mesylate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317867

CAS#: 67227-57-0

Description: Fenoldopam mesylate is a synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is used as an antihypertensive agent. It was approved by the Food and Drug Administration (FDA) in September 1997. Since fenoldopam is the only intravenous agent that improves renal perfusion, in theory it could be beneficial in hypertensive patients with concomitant renal insufficiency.

Chemical Structure

Fenoldopam mesylate

CAS# 67227-57-0

Instruction

Theoretical Analysis

MedKoo Cat#: 317867
Name: Fenoldopam mesylate
CAS#: 67227-57-0
Chemical Formula: C17H20ClNO6S
Exact Mass: 0.00
Molecular Weight: 401.860
Elemental Analysis: C, 50.81; H, 5.02; Cl, 8.82; N, 3.49; O, 23.89; S, 7.98

Price and Availability

Size	Price	Availability
10mg	USD 300	2 Weeks
25mg	USD 550	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Fenoldopam mesylate, Corlopam, SKF 82526J; SKF-82526J; SKF82526J

IUPAC/Chemical Name: 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol methanesulfonate

InChi Key: CVKUMNRCIJMVAR-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H16ClNO3.CH4O3S/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;1-5(2,3)4/h1-4,7,13,18-21H,5-6,8H2;1H3,(H,2,3,4)

SMILES Code: OC1=CC=C(C2CNCCC3=C2C=C(C(O)=C3Cl)O)C=C1.CS(=O)(O)=O

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 401.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Naeem M, McEnteggart GE, Murphy TP, Prince E, Ahn S, Soares G. Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis. Clin Imaging. 2015 Sep-Oct;39(5):759-64. doi: 10.1016/j.clinimag.2015.02.003. Epub 2015 Feb 12. Review. PubMed PMID: 25709111.

2: Caixeta A, Dogan O, Weisz G. Contrast-induced nephropathy: protective role of fenoldopam. Clin Exp Pharmacol Physiol. 2012 Jun;39(6):497-505. doi: 10.1111/j.1440-1681.2012.05707.x. Review. PubMed PMID: 22642656.

3: Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, Calabrò MG, Sheiban I, Tumlin JA, Ranucci M, Zangrillo A. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2008 Feb;22(1):27-33. doi: 10.1053/j.jvca.2007.07.015. Epub 2007 Nov 7. Review. PubMed PMID: 18249327.

4: Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG, Ranucci M, Zangrillo A. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis. 2007 Jan;49(1):56-68. Review. PubMed PMID: 17185146.

5: Walker PD, Brokering KL, Theobald JC. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy. 2003 Dec;23(12):1617-26. Review. PubMed PMID: 14695041.

6: Thompson EJ, King SL. Acetylcysteine and fenoldopam. Promising new approaches for preventing effects of contrast nephrotoxicity. Crit Care Nurse. 2003 Jun;23(3):39-46. Review. PubMed PMID: 12830779.

7: Mathur VS. The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev Cardiovasc Med. 2003;4 Suppl 1:S35-40. Review. PubMed PMID: 12556736.

8: Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine. Rev Cardiovasc Med. 2003;4 Suppl 1:S15-20. Review. PubMed PMID: 12556733.

9: Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med. 2001;2 Suppl 1:S4-8. Review. PubMed PMID: 12439361.

10: Vijayakumar E. New drugs: fenoldopam mesylate, glycoprotein IIb/IIIa antagonists, and K+ATP-channel agonists. Int Anesthesiol Clin. 2002 Winter;40(1):35-60. Review. PubMed PMID: 11910249.

11: Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001 Nov 22;345(21):1548-57. Review. PubMed PMID: 11794223.

12: Shorten GD. [Fenoldopam: potential clinical applications in heart surgery]. Rev Esp Anestesiol Reanim. 2001 Dec;48(10):487-91. Review. Spanish. PubMed PMID: 11792308.

13: Chu VL, Cheng JW. Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann Pharmacother. 2001 Oct;35(10):1278-82. Review. Erratum in: Ann Pharmacother 2002 Feb;36(2):346. Ann Pharmacother 2001 Dec;35(12):1677. PubMed PMID: 11675860.

14: Strauser LM, Pruitt RD, Tobias JD. Initial experience with fenoldopam in children. Am J Ther. 1999 Sep;6(5):283-8. Review. PubMed PMID: 11329109.

15: Oparil S, Aronson S, Deeb GM, Epstein M, Levy JH, Luther RR, Prielipp R, Taylor A. Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens. 1999 Jul;12(7):653-64. Review. PubMed PMID: 10411362.

16: Post JB 4th, Frishman WH. Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies. J Clin Pharmacol. 1998 Jan;38(1):2-13. Review. PubMed PMID: 9597553.

17: Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs. 1997 Oct;54(4):634-50. Review. PubMed PMID: 9339965.

18: Nichols AJ, Ruffolo RR Jr, Brooks DP. The pharmacology of fenoldopam. Am J Hypertens. 1990 Jun;3(6 Pt 2):116S-119S. Review. PubMed PMID: 1974439.

19: Holcslaw TL, Beck TR. Clinical experience with intravenous fenoldopam. Am J Hypertens. 1990 Jun;3(6 Pt 2):120S-125S. Review. PubMed PMID: 1974440.

Your view history

Fenoldopam mesylate featured